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ABSTRACT 
An accurate, precise, sensitive and reproducible High-performance liquid chromatographic (HPLC) and UV spectrophotometric 
methods were developed and validated for the quantitative determination of haloperidol (HPD) in bulk drug and pharmaceutical 
formulation. Different analytical performance parameters such as linearity, precision, accuracy, specificity, limit of detection (LOD) 
and limit of quantification (LOQ) were determined according to International Conference on Harmonization ICH Q2B guidelines. 
The RP-HPLC method was developed by the isocratic technique on a reversed-phase Thermo C18 (250 × 4.6 mm, 5µm) column 
with mobile phase consisting of Methanol: Acetonitrile (50:50v/v) at flow rate of 1.0 ml/min. The retention time for HPD was 
2.238±0.3min. The UV spectrophotometric determinations were performed at 244 nm using 80% methanol as a solvent. The 
linearity range for HPD was 5-25 μg/ml for both HPLC and UV method. The linearity of the calibration curves for each analyte in 
the desired concentration range was good (r2 >0.999) by both the HPLC and UV methods. The method showed good reproducibility 
and recovery with percent relative standard deviation less than 2%. Moreover, the accuracy and precision obtained with HPLC co-
related well with the UV method which implied that UV spectroscopy can be a cheap, reliable and less time consuming alternative 
for chromatographic analysis. The proposed methods are highly sensitive, precise and accurate and hence successfully applied for 
determining the assay and in vitro dissolution of a marketed formulation. 
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INTRODUCTION 
Haloperidol (HPD) is a tertiary amine that occurs as a 
white or almost white powder, is practically insoluble in 
water and is slightly soluble in alcohol, methanol and 
methylene chloride
1
. Haloperidol is an orally 
administered dopamine inverse agonist of the typical 
antipsychotic class of medication that chemically 
belongs to butyrophenone group
2
. Its mechanism of 
action is mediated by blockade of D2 dopamine 
receptors in the mesocortex and the limbic system of the 
brain
3
. Haloperidol is used to treat certain psychiatric 
conditions including schizophrenia, maniac states, 
medicament induced psychosis and neurological 
disorders with hyperkinesias
4
. It is also used to treat 
extreme behavior problems in children and to ease the 
symptoms of tourett’s syndrome. The dose of 
haloperidol for the treatment of schizophrenia is 5-
15mg/day with an average of 10mg per day. Its 
therapeutic plasma concentrations are in the range of 4–
20ng/ml. Most common dosage forms are tablets, oral 
solutions and injections. Side effects related to 
haloperidol are extrapyramidal including acute dystonic 
reactions, akathisia syndrome, drug induced 
Parkinsonism, bradykinesia and tardive dyskinesia
5
. 
Haloperidol is chemically 4-[4-(4-chlorophenyl)- 4-
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hydroxypiperidino] 4’- fluorobutyrophenone (Fig.1).The 
molecular formula of haloperidol is C21H23ClFNO2 and 
molecular weight is 375.86 g/mol. It is officially 
recognized in Indian Pharmacopoeia
6
, British 
Pharmacopoeia
7
. Haloperidol is metabolized to several 
metabolites
8
 and the enzymes involved in the 
biotransformation of haloperidol include cytochrome 
P450, carbonyl reductase and uridine diphosphoglucose 
glucuronosyltransferase. The greatest proportion of the 
intrinsic hepatic clearance of haloperidol is by 
glucuronidation followed by the reduction of haloperidol 
to reduced haloperidol and by cytochrome P450-
mediated oxidation
9
.  
 
Figure 1: Chemical structure of haloperidol 
Various analytical techniques have been used for 
determination of haloperidol   individually   and in 
combination with other drugs in pharmaceutical 
formulations, in human serum, human plasma and urine 
by RP- HPLC
10-19
 and UV spectrophotometry
20-23
, High 
performance thin-layer chromatography (HPTLC)
24
, 19F 
NMR spectroscopy
25
, square-wave adsorptive stripping 
voltammetry at a mercury electrode
26
, Non-aqueous 
titrimetric method has also been developed for 
haloperidol determination in pharmaceutical 
preparations 
27
. However there is no combine method 
available for the determination of HPD drugs. Therefore, 
an attempt was made to develop a new, rapid and 
sensitive method for the determination of HPD in bulk 
drug and pharmaceutical formulation. To assess the 
reproducibility and wide applicability of the developed 
method, it was validated as per ICH guidelines 
28
. 
EXPERIMENTAL 
Reagents and chemicals 
Pure sample of Haloperidol was received as a gift 
sample from Vamsi Labs. Ltd. Sholapur, Maharashtra, 
India. Acetonitrile (HPLC Grade), methanol (HPLC 
Grade), supplied by Merck Ltd, New Delhi, India. Triple 
distilled water was generated in house. Tablet Depidol 
5mg Torrent Lab. Pvt. Ltd. Ahmedabad, India was 
purchased from local market. 
Instrument 
In UV-spectrophotometric method, Labindia model- 
3000 + series were used, which is a wavelength accuracy 
±1 nm, with 1cm quartz cells. 
Liquid chromatographic system from Waters model no 
784 comprising of manual injector, water 515 binary 
pump for constant flow and constant pressure delivery 
and UV-Visible detector connected to software Data Ace 
for controlling the instrumentation as well as processing 
the generated data.  
UV spectrophotometric method 
Determination of wavelength of maximum 
absorbance (max) of HPD 
Wavelength of maximum absorption was determined by 
scanning 10µg/ml solution of HPD using UV 
spectrophotometer from 200 to 400 nm. This showed 
maximum absorbance at 244.0 nm (Fig. 2).  
Preparation of standard stock solution 
10 mg of HPD was weighed accurately and transferred 
to a 10ml volumetric flask and the volume was adjusted 
to the mark with the diluents (Methanol: water 80:20 
v/v), to give a stock solution of 1000ppm. 
Preparation of working standard solution 
From stock solutions of HPD, 1 ml was taken and 
diluted up to 10 ml, from this solution 0.5, 1.0, 1.5, 2.0 
and 2.5 ml solutions were transferred to 10ml volumetric 
flasks and make up the volume up to 10 ml with 80% 
methanol gives standard drug solution of 5, 10, 15, 20, 
25μg/ ml concentration. 
Preparation of the calibration curves of the drug 
The calibration curve was prepared by scanning test 
samples ranging from 5-25μg/ ml at 244 nm for HPD. 
The calibration curve was tested by validating it with 
inter-day and intra-day measurements. Mean of n =5 
determinations was plotted as the standard curve (Fig.3). 
RP-HPLC method 
Chromatographic condition 
The isocratic mobile phase consisted of Methanol: 
Acetonitrile in the ratio of (50:50 v/v), flowing through 
the column at a constant flow rate of 1.0 ml/ min. 
 
The 
mobile phase was filtered through nylon 0.22 µm 
membrane filters and was degassed before use (30 min).
 
A Thermo (C-18) Column (5 µm, 250mm x 4.60mm) 
was used as the stationary phase. By considering the 
chromatographic parameter, sensitivity and selectivity of 
method for drugs, 244 nm was selected as the detection 
wavelength for UV-Visible detector.  
Standard preparation 
Standard stock solution  
10mg of HPD was weighed accurately and transferred to 
separate 10 ml volumetric flask, and the volume was 
adjusted to the mark with methanol to give a stock 
solution of 1000 g/ml. 
Working standard solution  
From stock solutions of HPD 1 ml was taken and diluted 
up to 10 ml with methanol. From this solution 0.5, 1.0, 
1.5, 2.0, 2.5 ml solutions were transferred to 10ml 
volumetric flasks and make up the volume up to 10 ml 
with methanol, gives  standard drug solution of 5, 10, 
15, 20, 25 µg/ ml concentration. 
Preparation of calibration curve 
The calibration curve was prepared by injecting 
concentration of 5-25 µg/ml for HPD solutions manually 
in triplicate to the HPLC system at detection wavelength 
of 244 nm. Mean of n =5 determinations was plotted as 
the standard curve (Fig.4). The calibration curve was 
tested by validating it with inter-day and intra-day 
measurements. Linearity, accuracy and precision were 
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determined for both inter day and intra-day 
measurements. 
System Suitability 
The system suitability parameter was carried out to 
verify that the analytical system was working properly 
and could give accurate and precise result. The six 
replicates of reference standard, 10 g/ml of HPD were 
injected separately and chromatogram was recorded. The 
result of system suitability parameter is reported in 
table1. 
Validation Parameters  
Linearity 
Linearity was studied by analyzing five standard 
solutions (n=5) in the range of 5-25 μg /m1 of HPD in 
both UV spectrophotometric and HPLC method. 
Calibration curves with concentration verses absorbance 
or peak area was plotted for each method and the 
obtained data were subjected to regression analysis using 
the least squares method. Linearity of HPD was 
established by response ratios of drug. Response ratio of 
drug was calculated by dividing the absorbance or peak 
area with respective concentration (Table 2). 
Accuracy 
The validity and reliability of the proposed methods was 
assessed by recovery studies at three different levels i.e. 
80 %, 100 % and 120 %. The recovery studies were 
carried out by adding known amount of standard 
solution of HPD to preanalysed tablet solutions. The 
resulting solutions were then re-analysed by proposed 
methods. In UV Spectrophotometric method, the value 
of mean recoveries was found to be in the range of 99.58 
% to 99.89 % for HPD. The value of SD and %RSD less 
than 2 indicate the accuracy of the method. In RP-HPLC 
method, the value of mean recoveries was found in the 
range of 99.88% to 100.07 % for HPD. Total amount of 
drug found and percentage recovery was calculated. 
Results of recovery studies are reported in Table 3. 
Specificity 
The method specificity was assessed by comparing the 
chromatograms (HPLC) and scans (UV) obtained from 
the drug and the most commonly used excipient mixture 
with those obtained from blank (excipient solution in 
water without drug). The excipients chosen are the ones 
used commonly in tablet formulation, which included di-
calcium phosphate (DCP), lactose, starch, micro- 
crystalline cellulose (MCC), polyvinyl pyrrolidone 
(PVP), sodium starch glycolate (SSG) and magnesium 
stearate. The drug to excipient ratio used was similar to 
that in the commercial formulations Fig 5. 
Precision 
Precision was determined by repeatability and 
intermediate precision of drug. Repeatability result 
indicates the precision under the same operating 
condition over short interval time. The intermediate 
precision study is expressed within laboratory variation 
on different days and analyst to analyst variation by 
different analyst. The value of SD and %RSD are less 
than 2 indicate the precision of method. Result of 
precision shown in table 4. 
Robustness 
For the robustness of the analytical method we changed 
the ratio of mobile phase. As a replacement for the 
methanol: acetonitrile in a ratio of 50:50v/v, methanol: 
acetonitrile in a ratio of 55:45 v/v were used as solvent 
(Results are shown in Table 4).  
LOD and LOQ 
LOD and LOQ of described method were observed as 
0.404µg/ml and 1.200µg/ml for HPD in UV 
spectrophotometric method and 0.570 g/ml and 0.500 
g/ml for HPD in RP-HPLC method, based on the SD of 
response and slope, which meet the requirement of new 
method. 
Analysis of marketed formulation 
20 tablets (Depidol 5 mg) were weighed and ground to a 
fine powder. An equivalent amount to 5 mg of HPD was 
taken in 10 ml volumetric flask. This was dissolve in 5 
ml of diluents by sonication for about 10 minutes. The 
volume was made up to the mark by diluents as per the 
UV spectrophotometry method and RP-HPLC method. 
The solutions were filtered (whatman filter paper no.41). 
The filtrate was used to prepare samples of different 
concentration. The statistical evaluation of tablet 
analysis by both methods is reported in Table 5. 
RESULT AND DISCUSSION 
RP-HPLC and UV-Spectrophotometric methods were 
developed for HPD which can be conveniently 
employed for routine analysis in pharmaceutical dosage 
forms and will eliminate unnecessary tedious sample 
preparations. The chromatographic conditions were 
optimized in order to provide a good performance of the 
assay. The retention times (Rt) of HPD was 
2.238±0.3min. The chromatograms have been shown in 
Fig. 6. A five point calibration curve was constructed 
with working standards and was found linear (r2 = 
0.999) for each of the analytes over their calibration 
ranges. The slopes were calculated using the plot of drug 
concentration versus area of the chromatogram. The 
developed HPLC method was accurate, precise, 
reproducible and very sensitive. 
For UV Method: Y = 0.049 x +0.006 (r2= 0.999) 
For RP-HPLC:     Y = 120.7 x +31.48 (r2= 0.999) 
 
Figure 2: Selection of max of haloperidol 
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Figure 3: Calibration curves of the haloperidol 
 
Figure 4: Calibration graph of haloperidol 
 
Table 1: Results of system suitability parameters 
Parameters Haloperidol 
AUC 1285.245 
No. of Theoretical Plates 3039.000 
Tailing Factor 1.173 
Retention time 2.299 
 
Table 2: Response ratios of HPD 
Concentration 
(g/ml) 
HPLC Method UV Method 
Haloperidol AUC RR ABS RR 
5 635.654 127.131 0.250 0.050 
10 1290.236 129.024 0.501 0.050 
15 1874.458 124.964 0.751 0.050 
20 2436.654 121.833 1.012 0.050 
25 3045.589 121.824 1.214 0.048 
 
Table 3: Results of recovery study 
Recovery Level% % Mean±SD* 
 U.V Method RP-HPLC Method 
80% 99.58±0.629 100.07±0.994 
100% 99.93±0.416 100.03±0.208 
120% 99.89±0.834 99.88±0.278 
* Value of three replicate and three concentrations 
 
 
(A) 
 
(B)
Figure 5: UV scans (A) HPLC chromatograms (B) 
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Table 4: Results of precision 
Parameters UV Method RP-HPLC Method 
Precision (Mean± SD)* HPD %RSD HPD %RSD 
Repeatability 98.30±0.071 0.071 99.42±0.160 0.160 
Day to Day 99.57 ±0.109 0.109 99.13 ±0.546 0.550 
Analyst to Analyst 99.00±0.011 0.011 99.60 ±0.110 0.110 
Robustness* - - 99.24 ±0.170 0.171 
*Average of 5 replicate and 5 concentration. 
 
Table 5: Results and statistical parameters for tablet analysis 
S. No Drug Label 
claim 
Amount 
found 
% Label 
claimed 
SD* %RSD* 
UV Method HPD 5 4.98 99.60 1.61 1.61 
RP-HPLC HPD 5 4.95 99.00 1.83 1.84 
*Average of five determination 
 
 
Figure 6: Chromatogram of HPD 
 
All the method validation parameters are well within the 
limits as specified in the ICH Q2B guidelines. Table 3 
lists the percent recovery (content uniformity) of HPD 
in the commercial formulations by HPLC and UV 
methods. The intra- and inter-day precision (%R.S.D.) at 
different concentration levels was found to be less than 
2% (Table 4). Moreover the %R.S.D. (less variation) 
shows good precision of both developed methods. The 
calculated LOQ and LOD concentrations confirmed that 
the methods were sufficiently sensitive. The methods 
were specific as none of the excipients interfered with 
the analytes of interest. Hence, the methods were 
suitably employed for assaying HPD in commercial 
marketed formulation (Table 5). 
 
CONCLUSION 
The advantage of UV method over HPLC method is that 
the proposed UV method does not require the elaborate 
treatment and procedures usually associated with 
chromatographic method. It is less time consuming and 
economical. A statistical comparison of the quantitative 
determination of HPD shows that HPLC method as 
more accurate and precise than UV method. The results 
indicate HPLC and UV spectrotometry methods are 
adequate methods to quantify HPD in pure form and its 
dosage form. There was no interference by excipients in 
the tablets and the mobile phase is easy to prepare. Since 
these methods are simple, specific, rapid and accurate, 
they may be successfully and conveniently adopted for 
routine quality control analysis of HPD in bulk and 
pharmaceutical dosage form. 
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